πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 14,889 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11951159

Cattle fever tick-infestation vaccines and uses thereof

The United States of America, as represented by the Secretary of Agriculture Β· Granted Tue Apr 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11952364

TRK inhibitors useful as anticancer drugs

TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED Β· Granted Tue Apr 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11951176

Stabilization of glucagon by trehalose glycopolymer nanogels

The Regents of the University of California Β· Granted Tue Apr 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11944683

Pharmaceutical compositions comprising meloxicam

AXSOME THERAPEUTICS, INC. Β· Granted Tue Apr 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11944687

Carbohydrate conjugate RNA agents and process for their preparation

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Apr 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11945778

C4-carbonothioate-substituted tryptamine derivatives and methods of using

Enveric Biosciences Canada Inc. Β· Granted Tue Apr 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11944666

Treatment of inflammatory conditions delivery of interleukin-1 receptor antagonist fusion

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11945795

Islet cell manufacturing compositions and methods of use

Vertex Pharmaceuticals Incorporated Β· Granted Tue Apr 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11944658

Methods of heat inactivation of adenovirus

Ultragenyx Pharmaceutical Inc. Β· Granted Tue Apr 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11946065

Transgene cassettes, AAV vectors, and AAV viral vectors for expression of human codon-opti

The Board of Regents of the University of Texas System Β· Granted Tue Apr 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11946049

tRNA/pre-miRNA compositions and use in treating cancer

The Regents of the University of California Β· Granted Tue Apr 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11944679

Genome-wide identification of immune evasion functions in a virus

The Regents of the University of California Β· Granted Tue Apr 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11944617

Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxe

Corcept Therapeutics Incorporated Β· Granted Tue Apr 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11938124

Combination therapy for treatment of cancer

PMV PHARMACEUTICALS, INC. Β· Granted Tue Mar 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11938171

Therapeutic systems, devices, and compositions with wound healing and tissue regenerative

THE BIOREGENTECH INSTITUTE, INC. Β· Granted Tue Mar 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11938174

Compositions and methods useful for the treatment of neuromyelitis optica spectrum disorde

Takeda Pharmaceutical Company Limited Β· Granted Tue Mar 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11938177

Peptide vaccine formulations and use thereof for inducing an immune response

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Mar 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11938226

Abiotic anti-VEGF nanoparticle

The Regents of the University of California Β· Granted Tue Mar 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11939392

CD123 binding proteins and related compositions and methods

Aptevo Research and Development LLC Β· Granted Tue Mar 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11939581

Methods and compositions for targeting PD-L1

Aligos Therapeutics, Inc. Β· Granted Tue Mar 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11939345

Physiologically stable fluorophore and performing fluorescence probing

Government of the United States of America, as represented by the Secretary of Commerce Β· Granted Tue Mar 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11939346

Preparation of psilocybin, different polymorphic forms, intermediates, formulations and th

Compass Pathfinder Limited Β· Granted Tue Mar 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11939301

5HT1F receptor agonists and mitochondrial biogenesis

United States Government as represented by the Department of Veterans Affairs Β· Granted Tue Mar 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11939361

Compositions of peptide inhibitors of Interleukin-23 receptor

Protagonist Therapeutics, Inc. Β· Granted Tue Mar 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted